Smarter Chains, Safer Medicines: From Predictive Failures to Algorithmic Fixes in Global Pharmaceutical Logistics

Pharmaceutical manufacturing and logistics rely on accurate prediction and decision making to safeguard product quality, delivery reliability, and patient outcomes. Despite rapid advances in artificial intelligence (AI) and machine learning (ML), few studies benchmark model performance across the diverse operational demands of global pharmaceutical supply chains. Predictive setbacks contribute to financial losses, reduced supply chain efficacy, and potential adverse health consequences, yet understanding these failures offers firms opportunities to refine strategy and strengthen resilience. Drawing on 1.2 million shipments spanning 39 countries, we compare traditional statistical models (ARIMA), ensemble methods (random forests, gradient boosting), and deep neural networks (LSTM, GRU, CNN, ANN) across pricing, demand forecasting, vendor management, and shipment planning. Gradient boosting produced the strongest pricing performance, while ARIMA delivered the lowest demand-forecasting errors but with limited explanatory power; neural networks captured nonlinear demand shocks and achieved superior maintenance-risk classification. We also identified three vendor performance clusters—high-performing, cost-efficient, and mixed-reliability vendors—enabling firms to better align shipment criticality with vendor capabilities by prioritizing high performers for urgent deliveries, leveraging cost-efficient vendors for non-urgent volumes, and managing mixed performers through targeted oversight. These insights highlight the value of our evidence-based roadmap for selecting algorithms in high-stakes healthcare logistics, in rapidly evolving, technologically complex global contexts where increasing algorithmic sophistication elevates the standards for safer, smarter pharmaceutical supply chains.